Results 11 to 20 of about 73,736 (149)

Factors modulating 99mTc‐MAA planar lung dosimetry for 90Y radioembolization

open access: yesJournal of Applied Clinical Medical Physics, Volume 23, Issue 12, December 2022., 2022
Abstract Purpose To investigate the accuracy and biases of predicted lung shunt fraction (LSF) and lung dose (LD) calculations via 99mTc‐macro‐aggregated albumin (99mTc‐MAA) planar imaging for treatment planning of 90Y‐microsphere radioembolization.
Benjamin P. Lopez   +4 more
wiley   +1 more source

COMP Report: CPQR technical quality control guidelines for use of positron emission tomography/computed tomography in radiation treatment planning

open access: yesJournal of Applied Clinical Medical Physics, Volume 23, Issue 12, December 2022., 2022
Abstract Positron emission tomography with x‐ray computed tomography (PET/CT) is increasingly being utilized for radiation treatment planning (RTP). Accurate delivery of RT therefore depends on quality PET/CT data. This study covers quality control (QC) procedures required for PET/CT for diagnostic imaging and incremental QC required for RTP.
Ran Klein   +7 more
wiley   +1 more source

The application of multiple metrics in deformable image registration for target volume delineation of breast tumor bed

open access: yesJournal of Applied Clinical Medical Physics, Volume 23, Issue 12, December 2022., 2022
Abstract Background and purpose For postoperative breast cancer patients, deformable image registration (DIR) is challenged due to the large deformations and non‐correspondence caused by tumor resection and clip insertion. To deal with it, three metrics (fiducial‐, region‐, and intensity‐based) were jointly used in DIR algorithm for improved accuracy ...
Xin Xie   +6 more
wiley   +1 more source

A potential biomarker of cognitive impairment: The olfactory dysfunction and its genes expression

open access: yesAnnals of Clinical and Translational Neurology, Volume 9, Issue 12, Page 1884-1897, December 2022., 2022
Abstract Objective Accumulation evidence has reported that olfactory impairment may be an essential clinical marker and predictor of mild cognitive impairment or Alzheimer's disease. Method Participants were enrolled in the population‐based, prospective study in Fuxin county, Liaoning province, China between 2019 and 2021.
Jiayi Song   +11 more
wiley   +1 more source

Clinical utility of cerebrospinal fluid biomarkers measured by LUMIPULSE® system

open access: yesAnnals of Clinical and Translational Neurology, Volume 9, Issue 12, Page 1898-1909, December 2022., 2022
Abstract Objectives Cerebrospinal fluid (CSF) biomarkers of Alzheimer's disease (AD) are well‐established in research settings, but their use in routine clinical practice remains a largely unexploited potential. Here, we examined the relationship between CSF biomarkers, measured by a fully automated immunoassay platform, and brain β‐amyloid (Aβ ...
Hisashi Nojima   +9 more
wiley   +1 more source

Effects of pregnancy on neuromyelitis optica spectrum disorder and predictors of related attacks

open access: yesAnnals of Clinical and Translational Neurology, Volume 9, Issue 12, Page 1918-1925, December 2022., 2022
Abstract Objective Our study aimed to investigate the influence of pregnancy on the course of neuromyelitis optica spectrum disorders (NMOSD) and to explore the independent predictors of pregnancy‐related attacks. Methods We performed a retrospective study of patients with NMOSD based on the Wingerchuk 2006 or the revised Wingerchuk 2015 criteria ...
Qin Du   +7 more
wiley   +1 more source

Does long‐term phenytoin have a place in Dravet syndrome?

open access: yesAnnals of Clinical and Translational Neurology, Volume 9, Issue 12, Page 2036-2040, December 2022., 2022
Abstract Anti‐seizure medications that block sodium channels are generally considered contraindicated in Dravet syndrome. There is, however, considerable debate about the sodium‐channel blocker phenytoin, which is often used for status epilepticus, a frequent feature of Dravet syndrome.
George A. Zographos   +2 more
wiley   +1 more source

Impact of molecular diagnostics and targeted cancer therapy on patient outcomes (MODIFY): a retrospective study of the implementation of precision oncology

open access: yesMolecular Oncology, EarlyView.
The authors conducted a retrospective study of 94 patients with advanced cancer who underwent next‐generation sequencing (NGS) gene panel analysis and received targeted treatments when applicable. Results further support evidence indicating that molecular profiling provides clinical benefit.
Michaël Dang   +3 more
wiley   +1 more source

Cell‐free DNA aneuploidy score as a dynamic early response marker in prostate cancer

open access: yesMolecular Oncology, EarlyView.
mFast‐SeqS‐based genome‐wide aneuploidy scores are concordant with aneuploidy scores obtained by whole genome sequencing from tumor tissue and can predict response to ARSI treatment at baseline and, at an early time point, to ARSI and taxanes. This assay can be easily performed at low cost and requires little input of cfDNA. Cell‐free circulating tumor
Khrystany T. Isebia   +17 more
wiley   +1 more source

MET variants with activating N‐lobe mutations identified in hereditary papillary renal cell carcinomas still require ligand stimulation

open access: yesMolecular Oncology, EarlyView.
MET variants in the N‐lobe of the kinase domain, found in hereditary papillary renal cell carcinoma, require ligand stimulation to promote cell transformation, in contrast to other RTK variants. This suggests that HGF expression in the microenvironment is important for tumor growth in such patients. Their sensitivity to MET inhibitors opens the way for
Célia Guérin   +14 more
wiley   +1 more source

Home - About - Disclaimer - Privacy